Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
13 nov. 2023 16h05 HE
|
Avenue Therapeutics
- Phase 1b/2a clinical trial of AJ201 remains on track to report topline data in second quarter of 2024 - - Positive BAER-101 preclinical data accepted for presentation at American Epilepsy Society...
Fortress Biotech Announces Pricing of $10.0 Million Public Offering
10 nov. 2023 08h15 HE
|
Fortress Biotech, Inc.
MIAMI, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
Fortress Biotech Announces Launch of Proposed Public Offering
09 nov. 2023 17h05 HE
|
Fortress Biotech, Inc.
MIAMI, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
07 nov. 2023 16h01 HE
|
Journey Medical Corporation
Company generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023 GAAP net income increased to $16.8 million, or...
Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023
31 oct. 2023 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
26 oct. 2023 09h00 HE
|
Mustang Bio, Inc.
MB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical data...
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)
20 oct. 2023 08h30 HE
|
Journey Medical Corporation
Study demonstrated systemic exposure of DFD-29 was significantly lower than that of Solodyn (105 mg) Data presented at 43rd Annual Fall Clinical Dermatology Conference New Drug Application...
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer
18 oct. 2023 08h30 HE
|
Checkpoint Therapeutics, Inc
Cosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous...
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1
16 oct. 2023 09h00 HE
|
Fortress Biotech, Inc.
Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for...
Fortress Biotech Announces Reverse Stock Split
09 oct. 2023 12h50 HE
|
Fortress Biotech, Inc.
MIAMI, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...